Search

Your search keyword '"Podda G"' showing total 255 results
Start Over Author "Podda G"
255 results on '"Podda G"'

1. OC 29.1 Long-Term Outcomes of COVID-19 Associated Venous Thromboembolism (VTE)

Author

Ageno, W., primary, Antonucci, E., additional, Poli, D., additional, Bucherini, E., additional, Chistolini, A., additional, Fregoni, V., additional, Lerede, T., additional, Pancani, R., additional, Pedrini, S., additional, Pieralli, F., additional, Pignatelli, P., additional, Pizzini, A., additional, Podda, G., additional, Potere, N., additional, Sarti, L., additional, Testa, S., additional, Visonà, A., additional, and Palareti, G., additional

Published
2023
Full Text
View/download PDF

7. D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study

Author

Palareti, G., Poli, D., Pesavento, R., Legnani, C., Antonucci, E., Bucherini, E., Testa, S., Paoletti, O., Chistolini, A., Ceccato, D., Martinelli, I., Bucciarelli, P., Falanga, A., Tosetto, A., Sarti, L., Mastroiacovo, D., Cosmi, B., Visona, A., Santoro, R. C., Zanatta, N., Grandone, E., Bertu, L., Pengo, V., Caiano, L., Prandoni, P., Lotti, E., Crudele, F., Ageno, W., Abenante, A., Colombo, G., Guarascio, M., Cancellieri, E., Morandini, R., Zambelli, S., Martini, S., Vastola, M., Serrao, A., Abbattista, M., Artoni, A., Capecchi, M., Gianniello, F., Scimeca, B., Barcella, L., Gamba, S., Lerede, T., Maggioni, A., Schieppati, F., Russo, L., Zunino, F., Artuso, A., Bellesso, S., Cadau, J., Carli, G., Nichele, I., Perbellini, O., Caronna, A., Gabrielli, F., Lami, F., Nicolini, A., Scaglioni, F., Pinelli, M., Desideri, G., Borgese, L., Favaretto, E., Libra, A., Migliaccio, L., Sartori, M., Panzavolta, C., Scandiuzzi, T., Zalunardo, B. -M., Ierardi, A., Leotta, M., Strangio, A., Guzzon, S., Colaizzo, D., Favuzzi, G., Lombardi, M. R., Ferrini, P. M., Tassoni, M. I., Corradini, S., Iotti, M., Lambertini, I., Veropalumbo, M. R., Lessiani, G., Parisi, R., Bortoluzzi, C., H. N., Vo, Chiarugi, P., Casini, M., Violo, C., Nuti, M., Angeloni, L., Carrozzi, L., Pancani, R., Chimera, D., Conti, V., Meschi, C., Cattaneo, M., Podda, G., Birocchi, S., Cuppini, S., Marzolo, M., Milan, M., Martini, G., Merelli, S., Pontoglio, S., Portesi, N., Villalta, S., De Lucchi, L., Sponghiado, A., Becattini, C., Giustozzi, M., Vinci, A., Pignatelli, P., Bucci, T., Menichelli, D., Pastori, D., Pomero, F., Casalis, S., Galli, E., Ciammaichella, M., Maida, R., De Cristofaro, R., Alberelli, M. A., Basso, M. R., De Candia, E., Di Gennaro, L., Mumoli, N., Capra, R., Orlando, M., Porta, C., Rotiroti, G., Demarco, M., Petrillo, P., Rossi, E., Bartolomei, F., Soldati, D., Russo, U., Burgo, I., Ziliotti, M., Pataccini, C., Terroni, L., Ugolotti, M. C., Di Giorgio, A., Cavagna, L., Mete, F., Gino, M., Santoro, A., De Carlo, A., Cappelli, R., Bicchi, M., Dyrmo, L., Grifoni, E., Masotti, L., Ria, L., Spagnolo, M., Rupoli, S., Federici, I., Morsia, E., Scortechini, A. R., Torre, E., Franchini, M., Montorsi, P., Galgano, G., De Luca, A., Muiesan, M. L., Paini, A., Stassaldi, D., Denas, G., and Palareti G, Poli D, Ageno W, Legnani C, Antonucci E, Bucherini E, Testa S, Paoletti O, Chistolini A, Serrao A, Martinelli I, Bucciarelli P, Falanga A, Tosetto A, Sarti L, Mastroiacovo D, Cosmi B, Visonà A, Santoro RC, Zanatta N, Grandone E, Bertù L, Pengo V, Caiano LM, Prandoni P

Subjects
venous thromboembolism, d-dimer, anticoagulation therapy, apixaban, anticoagulation therapy, Recurrence, Settore MED/09 - MEDICINA INTERNA, D-dimer, venous thromboembolism, oral anticoagulants, apixaban, Humans, Anticoagulants, Hematology, Prospective Studies, Venous Thromboembolism, d-dimer
Abstract

D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE) for the risk of recurrence. However, this approach was never evaluated since direct oral anticoagulants are available. With this multicenter, prospective cohort study, we aimed to assess the value of an algorithm incorporating serial D-dimer testing and administration of reduced-dose apixaban (2.5 mg twice daily) only to patients with a positive test. A total of 732 outpatients aged 18 to 74 years, anticoagulated for ≥12 months after a first unprovoked VTE, were included. Patients underwent D-dimer testing with commercial assays and preestablished cutoffs. If the baseline D-dimer during anticoagulation was negative, anticoagulation was stopped and testing repeated after 15, 30, and 60 days. Patients with serially negative results (286 [39.1%]) were left without anticoagulation. At the first positive result, the remaining 446 patients (60.9%) were given apixaban for 18 months. All patients underwent follow-up planned for 18 months. The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval [CI], 4.5-11.2), including symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) recurrence, death for VTE, and major bleeding occurring in patients off anticoagulation vs that in those receiving apixaban (1.1%; 95% CI, 0.4-2.6; adjusted hazard ratio [HR], 8.2; 95% CI, 3.2-25.3). In conclusion, in patients anticoagulated for ≥1 year after a first unprovoked VTE, the decision to further extend anticoagulation should not be based on D-dimer testing. The results confirmed the high efficacy and safety of reduced-dose apixaban against recurrences. This trial was registered at www.clinicaltrials.gov as #NCT03678506.

Published
2022

8. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology

Author

Gresele, P., Falcinelli, E., Bury, L., Pecci, A., Alessi, M. -C., Borhany, M., Heller, P. G., Santoro, C., Cid, A. R., Orsini, S., Fontana, P., De Candia, E., Podda, G., Kannan, M., Jurk, K., Castaman, G., Falaise, C., Guglielmini, G., Noris, P., Zaninetti, C., Fiore, M., Tosetto, A., Zuniga, P., Miyazaki, K., Dupuis, A., Hayward, C., Casonato, A., Grandone, E., Mazzucconi, M. G., James, P., Fabris, F., Henskens, Y., Napolitano, M., Curnow, J., Gkalea, V., Fedor, M., Lambert, M. P., Zieger, B., Barcella, L., Cosmi, B., Giordano, P., Porri, C., Melazzini, F., Abid, M., Glembotsky, A. C., Ferrara, G., Russo, A., Deckmyn, H., Frelinger, A. L., Harrison, P., Mezzano, D., Mumford, A. D., Lordkipanidzé, M., BAT-VAL Study Investigators, Università degli Studi di Perugia = University of Perugia (UNIPG), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Unidad de Coagulopatías Congénitas. Hospital Universitario La Fe., Gresele, Paolo, Falcinelli, Emanuela, Bury, Loredana, Pecci, Alessandro, Alessi, Marie-Christine, Borhany, Munira, Heller, Paula G, Santoro, Cristina, Cid, Ana Rosa, Orsini, Sara, Fontana, Pierre, De Candia, Erica, Podda, Gianmarco, Kannan, Meganathan, Jurk, Kerstin, Castaman, Giancarlo, Falaise, Céline, Guglielmini, Giuseppe, Noris, Patrizia, Mariasanta Napolitano, Università degli Studi di Perugia (UNIPG), University of Perugia, Gresele, P., Falcinelli, E., Bury, L., Pecci, A., Alessi, M.-C., Borhany, M., Heller, P.G., Santoro, C., Cid, A.R., Orsini, S., Fontana, P., De Candia, E., Podda, G., Kannan, M., Jurk, K., Castaman, G., Falaise, C., Guglielmini, G., Noris, P., Zaninetti, C., Fiore, M., Tosetto, A., Zuniga, P., Miyazaki, K., Dupuis, A., Hayward, C., Casonato, A., Grandone, E., Mazzucconi, M.G., James, P., Fabris, F., Henskens, Y., Napolitano, M., Curnow, J., Gkalea, V., Fedor, M., Lambert, M.P., Zieger, B., Barcella, L., Cosmi, B., Giordano, P., Porri, C., Melazzini, F., Abid, M., Glembotsky, A.C., Ferrara, G., Russo, A., Deckmyn, H., Frelinger, A.L., Harrison, P., Mezzano, D., Mumford, A.D., Lordkipanidzé, M., and BAT-VAL Study Investigators

Subjects
medicine.medical_specialty, animal structures, mild&#8208, Platelet Function Tests, Platelet disorder, inherited platelet disorder, Hemorrhage, 030204 cardiovascular system & hematology, Hemorrhage/diagnosis, 03 medical and health sciences, 0302 clinical medicine, Von Willebrand factor, hemic and lymphatic diseases, Internal medicine, von Willebrand Factor, Von Willebrand disease, Medicine, Humans, Platelet, Bleeding prediction, Bleeding score, Blood platelet disorders, Child, Communication, Hemorrhage, Humans, Inherited platelet disorders, Mild-moderate bleeding disorders, Platelet Function Tests, von Willebrand diseases, von Willebrand Factor, Child, Blood Platelet Disorders, ddc:616, mild-moderate bleeding disorders, biology, business.industry, mild-moderate bleeding disorder, Incidence (epidemiology), Communication, Settore MED/09 - MEDICINA INTERNA, bleeding prediction, von Willebrand Diseases/diagnosis/genetics, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, medicine.disease, Blood Platelet Disorders/diagnosis/genetics, 3. Good health, bleeding score, Institutional repository, von Willebrand Diseases, moderate bleeding disorders, inherited platelet disorders, Quartile, biology.protein, von Willebrand disease, business
Abstract

Background: The ISTH Bleeding Assessment Tool (ISTH-BAT) has been validated for clinical screening of suspected von Willebrand disease (VWD) and for bleeding prediction. Recently it has been validated for subjects with inherited platelet disorders (IPD) (BAT-VAL study). Objectives: To determine whether the ISTH-BAT bleeding score (BS) predicts subsequent bleeding events requiring treatment in IPD patients. Methods: Patients with IPD, type 1 VWD (VWD-1) and age- and sex-matched healthy controls enrolled in the BAT-VAL study were prospectively followed-up for 2years and bleeding episodes requiring treatment were recorded. Results: Of the 1098 subjects initially enrolled, 955 were followed-up and 124 suffered hemorrhages during follow-up, 60% of whom had inherited platelet function disorders (IPFD). Total number of events was significantly higher in IPFD (n=235) than VWD-1 (n=52) or inherited thrombocytopenia (IT; n=20). Events requiring transfusions were 66% in IPFD, 5.7% in VWD-1, and 3% in IT. Baseline BS was significantly higher in IPFD patients with a bleeding event at follow-up than in those without (p&nbsp

Published
2021

15. New approaches for measuring coagulation

Author

BARROWCLIFFE, T. W., CATTANEO, M., PODDA, G. M., BUCCIARELLI, P., LUSSANA, F., LECCHI, A., TOH, C. H., HEMKER, H. C., BÉGUIN, S., INGERSLEV, J., and SØRENSEN, B.

Published
2006

17. Effects of laser photobiomodulation in the management of oral lichen planus: a literature review.

Author

Del Vecchio, A., Palaia, G., Grassotti, B., Tenore, G., Ciolfi, C., Podda, G., Impellizzeri, A., Mohsen, A., Galluccio, G., and Romeo, U.

Subjects
PHOTOBIOMODULATION therapy, ORAL lichen planus, CORTICOSTEROIDS, SQUAMOUS cell carcinoma
Abstract

Objectives. This review aims to understand whether Photobiomodulation (PBM) therapy is a valid aid in the management of Oral Lichen Planus (OLP) and its symptoms. Moreover, an analysis to determine whether it is a valid replacement for conventional therapies and whether standardized protocols can be used in PBM sessions or whether these should be changed depending on the type of injury has been made. Finally, an evaluation to determine whether PBM may induce transformation of dysplastic oral keratinocytes into squamous cell carcinoma has been made. Materials and Methods. Searches were conducted on two search databases for relevant publications released between 1992 and 2019. The databases used were: Pubmed "Medline", and Google Scholar. Forty-four articles complied with the inclusion criteria and were included for quality assessment and data extraction. Results. All the studies reported positive effects of PBM; however, there was wide heterogeneity in the laser parameters used in the management of the OLP. The effective dose ranges from 2 to 3 J/cm2, in order to see the desired biological effects. Conclusions. PBM is useful in controlling algal sensation and can be used in cases of OLP lesions that are not responsive to conventional therapies or when corticosteroid doses are too high for the patient, resulting in possible side effects. Standardized biostimulation protocols with further scientific insights are therefore required. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

19. Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016

Author

Mustazzolu, A., Borroni, E., Cirillo, D. M., Giannoni, F., Iacobino, A., Fattorini, L., Ghisetti, V., Mondo, A., Avolio, M., Barbui, A., Lorenzetti, P., De Renzi, G., Chirillo, M. G., Molinari, G., Camaggi, A., Andreoni, S., Piana, F., Marchese, A., Gritti, P., Icardi, G., Varnier, O., Mazzola, E., Gesu, G., Cichero, P., Lombardi, A., Libanori, E., Viggiani, P., De Lorenzo, S., Pinsi, G., Marone, P., Monzillo, V., Barbarini, D., Farina, C., Arosio, M., Peracchi, M., Manganelli, R., Fabris, C., Di Santolo, M., Busetti, M., Scarparo, C., Sartor, A., Pedrotti, C., Caola, I., Frizzera, E., Dal Monte, P., Pietrosemoli, P., Pecorari, M., Fabio, A., La Regina, A., Matteucci, M., Piersimoni, C., Bartolesi, A., Mannino, R., Simonetti, T., Tortoli, E., Rindi, L., Mencacci, A., Cenci, E., Luciano, E., Mazzolla, R., Sanguigni, I., Parisi, G., Chiaradonna, P., Altieri, A. M., D'Arezzo, S., Mazzarelli, A., Di Caro, A., Bordi, E., Sali, M., Delogu, G., Sanguinetti, M., Russo, C., Coltella, L., Ciocco, A., Meledandri, M., Gambi, A., Tomei, G., Conte, M., Santoro, G., Del Giudice, A., Nuzzolese, N., Vitullo, E., Sinno, A., Buono, L., Costa, D., Grimaldi, A., Di Taranto, A., De Nittis, R., Palumbo, G., Dodaro, S., Giraldi, C., Cavalcanti, P., Nistico, S., Vinci, L., Di Naso, C., Bonura, C., Maida, C. M., Mammina, C., Podda, G. S., Caddeu, R., Mustazzolu A., Borroni E., Cirillo D.M., Giannoni F., Iacobino A., Fattorini L., Ghisetti V., Mondo A., Avolio M., Barbui A., Lorenzetti P., De Renzi G., Chirillo M.G., Molinari G., Camaggi A., Andreoni S., Piana F., Marchese A., Gritti P., Icardi G., Varnier O., Mazzola E., Gesu G., Cichero P., Lombardi A., Libanori E., Viggiani P., De Lorenzo S., Pinsi G., Marone P., Monzillo V., Barbarini D., Farina C., Arosio M., Peracchi M., Manganelli R., Fabris C., Di Santolo M., Busetti M., Scarparo C., Sartor A., Pedrotti C., Caola I., Frizzera E., Dal Monte P., Pietrosemoli P., Pecorari M., Fabio A., La Regina A., Matteucci M., Piersimoni C., Bartolesi A., Mannino R., Simonetti T., Tortoli E., Rindi L., Mencacci A., Cenci E., Luciano E., Mazzolla R., Sanguigni I., Parisi G., Chiaradonna P., Altieri A.M., D'Arezzo S., Mazzarelli A., Di Caro A., Bordi E., Sali M., Delogu G., Sanguinetti M., Russo C., Coltella L., Ciocco A., Meledandri M., Gambi A., Tomei G., Conte M., Santoro G., Del Giudice A., Nuzzolese N., Vitullo E., Sinno A., Buono L., Costa D., Grimaldi A., Di Taranto A., De Nittis R., Palumbo G., Dodaro S., Giraldi C., Cavalcanti P., Nistico S., Vinci L., Di Naso C., Bonura C., Maida C.M., Mammina C., Podda G.S., and Caddeu R.

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, Emigrants and Immigrants, Humans, Italy, Mycobacterium tuberculosis, Rifampin, Tuberculosis, Multidrug-Resistant, 03 medical and health sciences, 0302 clinical medicine, polycyclic compounds, medicine, Tuberculosis, biology, business.industry, Extensively drug-resistant tuberculosis, Multidrug-Resistant, medicine.disease, biology.organism_classification, Virology, 030104 developmental biology, 030228 respiratory system, business, Rifampicin, medicine.drug
Abstract

In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016

Published
2018

20. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey

Author

Girmenia, C, Bertaina, A, Piciocchi, A, Perruccio, K, Algarotti, A, Busca, A, Cattaneo, C, Raiola, Am, Guidi, S, Iori, Ap, Candoni, A, Irrera, G, Milone, G, Marcacci, G, Scimè, R, Musso, M, Cudillo, L, Sica, S, Castagna, L, Corradini, P, Marchesi, F, Pastore, D, Alessandrino, Ep, Annaloro, C, Ciceri, F, Santarone, S, Nassi, L, Farina, C, Viscoli, C, Rossolini, Gm, Bonifazi, F, Rambaldi, A, Capria, S, Mastronuzzi, A, Pagliara, D, Bernaschi, P, Amico, L, Carotti, A, Mencacci, A, Bruno, B, Costa, C, Passi, A, Ravizzola, G, Angelucci, E, Marchese, A, Pecile, P, Ventura, G, Fanin, R, Scarparo, C, Barbaro, A, Leotta, S, Marchese, Ae, Becchimanzi, C, Donnarumma, D, Tringali, S, Baldi, Mt, Scalone, R, Picardi, A, Arcese, W, Fontana, C, Giammarco, S, Spanu, T, Crocchiolo, R, Casari, E, Mussetti, A, Conte, E, Ensoli, F, Miragliotta, G, Marone, P, Arghittu, M, Greco, R, Forcina, A, Chichero, P, Di Bartolomeo, P, Fazii, P, Kroumova, V, Decembrino, N, Zecca, M, Pisapia, G, Palazzo, G, Lanino, E, Faraci, M, Castagnola, E, Bandettini, R, Pastano, R, Sammassimo, S, Passerini, R, Stefani, Pm, Gherlinzoni, F, Rigoli, R, Prezioso, L, Cambò, B, Calderaro, A, Carella, Am, Cascavilla, N, Labonia, Mt, Celeghini, I, Mordini, N, Piana, F, Vacca, A, Sanna, M, Podda, G, Corsetti, Mt, Rocchetti, A, Cilloni, D, De Gobbi, M, Bianco, O, Fagioli, F, Carraro, F, De Intinis, G, Severino, A, Proia, A, Parisi, G, Vallisa, D, Confalonieri, M, Russo, D, Malagola, M, Galieni, P, Falcioni, S, Travaglini, V, Raimondi, R, Borghero, C, Pavan, G, Prete, A, Belotti, T, Ambretti, S, Imola, M, Mianulli, Am, Pedna, Mf, Cesaro, S, Lo Cascio, G, Ferrari, A, Piedimonte, M, Santino, I, Calandrelli, M, Olivieri, A, Orecchioni, F, Mirabile, M, Centurioni, R, Gironacci, L, Caravelli, D, Gallo, S, De Filippi, M, Cupelli, L, Dentamaro, T, Falco, S, Eugenio, Os, Marotta, S, Risitano, A, Lula, D, Musto, P, Pietrantuono, G, Traficante, A, Cerchiara, E, Tirindelli, Mc, Dicuonzo, G, Chierichini, A, Anaclerico, B, and Placanica, P.

Published
2017

24. A computer program for the calculation of stresses and strains in the axisymmetric cup drawing

Author

Orlando, M., Pagannone, M., Perotti, G., and Podda, G.

Abstract

The proposed computer program is developed incorporating previous results by WOO, as well as taking into account the cup wall, whose exact solution had not been previously sought. The calculations are performed in this case starting both from the punch side as well as from the die side, so as to individuate the position of the section of the cup wall on both sides of which the computed values of stresses and strains are the same within defined limits. The results are in this way generalized to cup walls that form contact angles different from 90° with the initial blank position.

Published
2013

29. Molecular detection of virulence factors and antibiotic resistance pattern in clinical Enterococcus faecalis strains in Sardinia

Author

Cosentino, S., Podda, G. S., Corda, A., Fadda, M. E., Deplano, M., and Maria Barbara Pisano

Abstract

In this study, the antibiotic resistance pattern and the presence of genes encoding several virulence factors in 91 Enterococcus faecalis strains isolated from different human clinical sources in Sardinia were investigated. Genotypic determination of virulence genes (gelE, esp, agg, ace, cylA,B,M,LL,LS, efaA, fsrB) was car- ried out by PCR. The production of gelatinase and haemolytic activity were also determined. Antimicrobial susceptibility tests were performed by an automated microdilution test (Vitek). The strains examined in this study contained at least one and up to as many as all virulence genes investigated. Examining the distribu- tion of these factors in the different groups of clinical strains, we found that all but one virulence determinant were detected more frequently among urinary isolates. The detection of some factors by PCR did not always correlate with its phenotypic expression. Antibiotic susceptibilities among the Enterococcus faecalis strains investigated in our study were typical for the species, with expected levels of acquired resistance. Faecal iso- lates had the highest percentage of resistance, especially to high level-gentamicin, ciprofloxacin and norfloxacin. In summary, a wide variety of genes encoding virulence factors have been detected among our clinical Enterococcus faecalis strains, and those isolated from UTI were characterized by a higher virulence potency compared with strains from other clinical sources. Silent virulence genes (cyl or gelE) were frequently detected, therefore both the genotypic and phenotypic assays seem necessary for a better characterization of the strains. Our results may serve as a basis for additional surveillance studies of infections caused by this microorganism., Journal of Preventive Medicine and Hygiene, Vol 51, No 1 (2010)

Published
2010
Full Text
View/download PDF

30. Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey

Author

Fadda, M. E., Podda, G. S., Maria Barbara Pisano, Deplano, M., and Cosentino, S.

Abstract

Over a three years period, 472 Candida isolates were obtained from specimens of patients hospitalized either in ?at risk?, Bone Marrow Transplant Unit and Intensive Care Unit, or in conventional wards, Pneumological Divisions of the ?Binaghi? Hospital of Cagliari (Italy). Antifungal susceptibility profile to amphotericin B, voriconazole, fluconazole and ketoconazole was determined. Candida albicans was the predominant species while Candida krusei was the most frequent non-albicans species. C. krusei was significantly more common among Bone Marrow Transplant Unit and Intensive Care Unit than Pneumological Divisions patients (17.9% and 14.1% vs. 6.0%; p inf. 0.05). No significant differences were observed when the same distribution was analysed with regard to the other Candida species or when Bone Marrow Transplant Unit and Intensive Care Unit were compared. The profiles of susceptibility to the antifungal drugs among isolates from the different hospital wards showed no significant differences, even though most of MIC values were higher for Intensive Care Unit isolates compared to those for Bone Marrow Transplant Unit and Pneumological Divisions. For C. albicans isolates, amphotericin B was the more efficient antifungal (97.7% S), while fluconazole (6.1% R [Resistant] and 2.6% SDD [Susceptible Dose Dependent]) and ketoconazole (4.1% R and 3.2% SDD) showed the lowest activity. Voriconazole was the more efficient antimycotic for C. krusei (96.7% S) and Candida glabrata (100% S [Sensible]) isolates. This study has shown a significantly higher presence of nonalbicans Candida in at risk wards as well as a decreased susceptibility to the older azoles (ketoconazole and fluconazole) among C. albicans isolates., Journal of Preventive Medicine and Hygiene, Vol 49, No 2 (2008)

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results